Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
Piunti A, Meghani K, Yu Y, Robertson AG, Podojil JR, McLaughlin KA, You Z, Fantini D, Chiang M, Luo Y, Wang L, Heyen N, Qian J, Miller SD, Shilatifard A, Meeks JJ. Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma. Sci Adv. 2022 10 07; 8(40):eabo8043.
-
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines? Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 08; 20(8):866-878.
-
Miron B, Handorf E, Zarrabi K, Zibelman MR, Anari F, Ghatalia P, Plimack ER, Geynisman DM. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. Urol Oncol. 2022 10; 40(10):454.e9-454.e16.
-
Shvero A, Laufer M, Zilberman DE, Winkler H, Dotan ZA, Kleinmann N. [UPPER TRACT UROTHELIAL CARCINOMA]. Harefuah. 2021 Sep; 160(9):619-624.
-
Vuille-Lessard ?, Montani M, Bosch J, Semmo N. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. J Autoimmun. 2021 09; 123:102710.
-
Allen BC, Oto A, Akin O, Alexander LF, Froemming AT, Fulgham PF, Halpern DJ, Gettle LM, Maranchie JK, Patel BN, Patlas MN, Schieda N, Solanki A, Turkbey IB, Venkatesan AM, Yoo DC, Lockhart ME. ACR Appropriateness Criteria? Post-Treatment Surveillance of Bladder Cancer: 2021 Update. J Am Coll Radiol. 2021 May; 18(5S):S126-S138.
-
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 04; 22(4):525-537.
-
Hale O, Patterson K, Lai Y, Meng Y, Li H, Godwin JL, Homet Moreno B, Mamtani R. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. Clin Genitourin Cancer. 2021 02; 19(1):e17-e30.
-
Podojil JR, Glaser AP, Baker D, Courtois ET, Fantini D, Yu Y, Eaton V, Sivajothi S, Chiang M, Das A, McLaughlin KA, Robson P, Miller SD, Meeks JJ. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma. Oncoimmunology. 2020; 9(1):1744897.
-
Sklar BA, Gervasio KA, Karmazin K, Wu AY. Orbital Metastasis From Urothelial Carcinoma: A Comprehensive Literature Review. Ophthalmic Plast Reconstr Surg. 2019 May/Jun; 35(3):213-217.